PENGARUH TERAPI N-ASETILSISTEIN TERHADAP KADAR INTERCELLULAR ADHESION MOLECULE-1 (ICAM-1) DAN OXIDIZED LOW DENSITY LIPOPROTEIN (Ox-LDL) PADA PASIEN DIABETES MELITUS TIPE 2

Kirana, Shanti (2017) PENGARUH TERAPI N-ASETILSISTEIN TERHADAP KADAR INTERCELLULAR ADHESION MOLECULE-1 (ICAM-1) DAN OXIDIZED LOW DENSITY LIPOPROTEIN (Ox-LDL) PADA PASIEN DIABETES MELITUS TIPE 2. Other thesis, Universitas Sebelas Maret.

[img] PDF - Published Version
Download (312Kb)

    Abstract

    Shanti Kirana. S961308005. The therapeutic Effect of N-acetylcysteine on Levels Intercellular Adhesion Molecule-1 (ICAM-1) and Oxidized low-density lipoprotein (Ox-LDL) in patients with diabetes mellitus type 2. THESIS. Supervisor: Prof. Dr. H.M Bambang Purwanto, dr. KGH Sp.PD FINASIM. Specialist Education Program I. Internal Medicine.Sebelas Maret University Surakarta. ABSTRACT Background Type 2 diabetes mellitus shown to be associated with endothelial dysfunction that plays a role in the pathogenesis and clinical manifestations of atherosclerosis. Hyperglycemia leads to glucose autooksidasi forming free radicals (oxidative stress), increased protein glycation, and increased polyol pathway that decreases endogenous antioxidants. ICAM-1 is a marker of inflammation which is adhesion molecule activated by pro-inflammatory cytokines expressed by NFKβ. Diabetes mellitus is an increase in non-enzymatic glycated LDL, decreased retrieval by and catabolism of LDL receptors and changes in the coagulation system. N-aetilsistein a thiol-containing compounds with antioxidant and anti-inflammatory effects. N-acetylcysteine antioxidant effects occur directly through interaction with ROS electrophilic or as precursors of glutathione, can protect cells from oxidative stress Research Purpose This study aims to know and compare the therapeutic effect of N-acetylcysteine on levels of ICAM-1 and Ox-LDL levels of patients with type 2 diabetes. Research Methods This research uses experimental study design, randomized controlled trial, 40 subjects with type 2 diabetes patients is divided into two: control group (standard therapy + placebo) and treatment group (standard therapy + N-acetylcysteine) for 4 weeks. Data is presented in the form of mean ± SD and analyzed using SPSS 22 for windows, value of p <0.05 was considered statistically significant. Mean different test used to determine the mean difference between the groups N-acetylcysteine and placebo before and after treatment are used independent samples t test (normal data distribution) and Mann Whitney test was used (the distribution is not normal). To determine the mean difference between before to after treatment in a group of paired samples t test was used when the data were normally distributed (if not normally used Wilcoxon test). Research Result ICAM-1 levels before and after treatment to placebo (338,10±373,61)ng/mL and (281,20±165,0)ng/ml, Ox-LDL (1707,4±332,64)pg/ml and (1818,70±220,0)pg/ml., group N-acetylcysteine levels of ICAM-1(292,05±118,05) mg/dl dan (194,50±67,85) ng/mL, Ox-LDL (1877,40±310,27)pg/ml dan (1352±255,02)pg/ml. The results of 2 mean by Mann Whitney test for variable delta-ICAM-1 in the placebo group and N-acetylcysteine group (56,9 ± 223,11)ng/mL dan (97,55 ± 68,49)ng/mL showed significant differences (p =0.001). The results of 2 mean difference for variable delta-oxLDL in the placebo group and N-acetylcysteine group (-111,30 ± 237,73)pg/ml and (524,45 ± 273,62)pg/ml showed the difference was significant (p = 0.001). Conclusion :N-acetylcysteine therapy in patients with type 2 diabetes can significantly reduce levels of ICAM-1 and Ox-LDL. Keywords: N-acetylcysteine, ICAM-1, oxLDL, type 2 diabetes melitus

    Item Type: Thesis (Other)
    Subjects: R Medicine > R Medicine (General)
    Divisions: Fakultas Kedokteran > Spesialis Ilmu Penyakit Dalam
    Depositing User: Indrawan indra
    Date Deposited: 24 Nov 2017 10:02
    Last Modified: 24 Nov 2017 10:02
    URI: https://eprints.uns.ac.id/id/eprint/36228

    Actions (login required)

    View Item